Bodisen Biotech Will Report Record First
Tuesday May 10,
9:30 am ET
NEW YORK--(BUSINESS WIRE)--May 10, 2005--Bodisen Biotech, Inc.,
(OTCBB: BBOI, website: /)
announced today that it anticipates substantial growth in earnings
from the production and sale of its unique organic fertilizer
products for the first quarter of 2005, as compared to the
corresponding period in 2004.
The completion of its state of the art manufacturing facility at
the beginning of the first quarter gave Bodisen the capability to
dramatically increase the orders that it was able to take from
customers. Bodisen also ordered an additional three sets of new
production lines, which further expanded the company's production
capabilities in the first quarter.
Ms. Qiong Wang, CEO of Bodisen, commented "We are delighted with
our progress in the first quarter of 2005, typically not the
strongest quarter for the industry in China. The substantial
increase in our production capabilities has allowed us to make up
ground on the increasing demand being shown from farmers in China
for organic fertilizers. We look forward to announcing results for
the first quarter shortly which we anticipate will meet the high
expectations of our shareholders."
Utilizing proprietary technologies, Bodisen sells over 60
packaged products in 3 product categories: Organic Compound
Fertilizer; Organic Liquid Fertilizer; and Pesticides &
Insecticides. Bodisen's organic fertilizers can be absorbed by
plants within 48 hours while enriching soil conditions without the
damaging effects associated with chemical fertilizers.
About Bodisen Biotech, Inc.
Bodisen is headquartered in Shaanxi, China, an agricultural hub
of China and the economic gateway to the western regions of China.
The Bodisen brand is a highly respected organic brand in China. Its
"green" products support the mandate of the Chinese national
government to increase crop yields for the purpose of decreasing
China's dependency on food imports.
Safe Harbor Statement
This press release may contain forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are based
on the current expectations or beliefs of Bodisen Biotech, Inc.
management and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements.